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Abstract-The effects of benzomorphans, tricyclic antidepressants, monoamine oxidase 
(MAO) inhibitors and chlorpromazine on the microsomal (Na+ + K+)-adenosine 
triphosphatase (ATPase) from beef cerebral cortex were studied. As a comparison, the 
interaction of these drugs with the corresponding enzyme from kidney cortex was also 
investigated. In addition to chlorpromazine, the benzomorphans and the tricyclic 
antidepressants inhibited the brain enzyme considerably, whereas the MAO inhibitors 
had little effect. The (Na+ + K+)-ATPase from kidney was not affected by the benzo- 
morphans or MAO inhibitors, but its activity diminished in the presence of the tricyclic 
antidepressants and chlorpromazine. 
THE EXISTENCE of an (Na+ + K+)-activated adenosine triphosphatase (ATPase) in a 
variety of tissues is well d0cumented.l The highest activities of this enzyme were 
found in nervous tissue.2 The enzyme is intimately associated with membranes, but its 
solubilization has recently been achieved. 3 Considerable evidence indicates the 
involvement of this enzyme in the active transmembrane transport of Na+ and JS+.4,s 
Lower aliphatic alcohols, including ethanol, as well as several general depressants 
have been reported to inhibit the brain (Na+ + K+)-ATPase.6-g It has also been 
shown that the lower alcohols produced an inhibition of cation transport in brain 
slices.7 Inhibitory effects of imipramine on the brain microsomal (Na+ + K+)-ATPase 
under various experimental conditions were reported previously.lO*ll 
In view of the apparent interaction of general depressants with the cell membrane, 
including the brain (Na’ + K+)-ATPase, it was of interest to investigate the effect of 
drugs having analgesic or antidepressant activity on this enzyme. As a comparison, 
the interaction of these compounds with the (Na+ + K+)-ATPase isolated from kidney 
cortex was also studied. 
EXPERIMENTAL PROCEDURE 
Materials. Beef brains and kidneys were generously supplied by Standard Beef Co., 
Detroit, and Russell B. Slaughter House, Ypsilanti, Mich. respectively. All common 
chemicals were of reagent grade. The sources of drugs were: Merck (amitriptyline), 
Geigy (desipramine, imipramine), Smith, Kline & French (chlorpromazine, phena- 
zocine, tranylcypromine), Winthrop (pentazocine, cyclazocine), Ciba (hydralazine) 
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and Warner-Chilcott (phenelzine). Etazocine was kindly supplied by Dr. .I. E. Villar- 
real, Department of Pharmacology, The University of Michigan. 
Preparation of enzymes. The organs from beef were transported in ice to the labor- 
atory within 1 hr after slaughter. The brain (Na+ + K+)-ATPase was prepared as 
described previously.12 The specific activity of the enzyme in the “heavy” microsomal 
fraction was 16.6 pmoles Pi/mg of protein/hr. The same procedure was used to prepare 
the (Na+ + K+)-ATPase from kidney cortex, except that the pH of the suspending 
medium during the isolation of the microsomal fraction was 7.5. The specific activity 
of the kidney enzyme was 7.9 pmoles Pi/mg of protein/hr. Protein was determined 
according to Lowry et al. l3 The microsomal enzyme preparations from both organs 
contained approximately 10 mg/ml of protein and were stored at - 70”. 
Enzyme assays. Aqueous solutions of the drugs (5 mg/ml) were prepared fresh 
prior to each experiment. If needed to achieve solubilization, the pH of the solution 
was adjusted to 4 with HCl. Chlorpromazine was protected from light. 
The incubation medium (pH 7.0) was prepared “double strength” and contained 
respective millimolar concentrations of: NaCl, 180, KCI, 6, MgCl,, 6, ATP, 6 and 
imidazol buffer, 50. The same basic incubation medium was used for both the brain 
and kidney enzyme, except that the latter was assayed at pH 7*5.14 The activity of the 
(Na+ & K+)-ATPase was calculated by subtracting the ouabain-insensitive ATPase 
from the total ATPase activity. Therefore, in addition to the basic incubation medium 
described above (medium A), a second medium containing in addition O-2 mM 
ouabain (medium B) was prepared. 
Three different incubations were performed with each drug studied. The enzyme 
preparations from brain and kidney were diluted 1: 80 with 50 mM imidazol-HCl, 
pH 7.0 and 7.5 respectively. To 200 ~1 of the diluted suspensions were added 200 ~1 of 
the incubation medium A, the set (four tubes) incubated for 10 min at 37”, then placed 
into an ice-water bath, and 5-55 pg of the investigated drug contained in l-10 ~1 of 
aqueous solution, added. The final concentration of the drugs during the incubation 
ranged from 0.4 x 10e4 to 1 x 10v3 M. The tubes were then incubated for 60 min 
at 37” (incubation set A). Further experimental details of the enzyme assay were 
described previously. lz Briefly, the enzymatic reaction was terminated with O-6 M 
HClO, and the inorganic phosphate liberated was determined in the protein-free 
supernatant by measuring the absorbance at 700 nm after the additon of a medium 
containing FeSO,, HzS04 and NH,-molybdate. The inorganic phosphate was quanti- 
tated from a standard curve obtained with known amounts of KH,PO,. 
In another set of tubes, the diluted enzyme preparation was preincubated with 
medium B, then the drug under study was added and the tubes were reincubated for 
60 min (incubation set B). 
In a third group of tubes, the enzyme was preincubated for 10 min with the ouabain- 
free medium (medium A) in the presence of the individual drug in concentrations as 
indicated, followed by the addition of ouabain to give a final concentration of 1 x IOF 
M and an additional incubation of 60 min (incubation set C). 
RESULTS 
In view of the antagonistic effect of K+ on the inhibition of the (Na+ + K+)- 
ATPase by cardiac glycosides, r2,15 its most potent inhibitors, all the experiments 
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reported in the present study were performed in the presence of 3 mM K+. This 
concentration was selected as a compromise between optimal conditions for measuring 
(Na+ + K+)-ATPase activity and for measuring its inhibition. 
The effect of tricyclic antidepressants on the (Na+ + K+)-ATPase isolated from 
the cortices of brain and kidney is shown in Fig. 1. Total inhibition of the enzyme by 
0.1 mM ouabain was used as a reference for plotting the per cent inhibition caused by 
various concentrations of the drugs. The indicated amounts (0.4-5 x 10W4 M) are 
those actually present during the incubation. Although a similar pattern of inhibition 
was obtained for both enzymes, the (Na+ + K+)-ATPase from brain was more 
susceptible to these drugs. Amitriptyline (0.2 x lob3 M), the most potent inhibitor 
of both enzymes, inhibited the brain enzyme twice as much as the enzyme from 
kidney. Interestingly, whereas the inhibition of both enzymes by amitriptyline and 
imipramine increased with rising concentrations of the drugs, the inhibition by desi- 
pramine showed saturation. The concentrations of imipramine which inhibited the 
microsomal (Na+ + K+)-ATPase from rat brain 9 and 25 per cent, respectively, were 
reported l”,ll as 1 x IO-“andO. x 10M3 M. 
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FIG, 1. Effect of tricyclic antidepressants on the microsomal (Na+ + K+)-ATPase from cortices of 
brain and kidney. The enzyme preparations were incubated with the indicated amounts of the drugs 
in the medium, as described in the text, containing 3 mM K +. The incubations were carried out and 
the enzyme activity was calculated as described in the text. Each experiment, using the same enzyme 
preparation, was run in quadruplicate and the values presented are the averages of three experiments. 
The standard deviation about these averages did not exceed 5 per cent of the mean value. 
In contrast to the tricyclic antidepressants, the drugs having antidepressant activity 
but belonging to the group of monoamine oxidase (MAO) inhibitors, present at 
concentrations of 0.1-I x 10m3 M, showed little inhibition of the brainenzyme (Fig. 2). 
Only 10 per cent inhibition of the (Na+ + K+)-ATPase from brain was obtained with 
hydralazine at a concentration of O-8 x lob3 M. These drugs had no effect on the 
enzyme from kidney over the concentration range stated above. 
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FIG. 2. Effect of MAO inhibitors on the microsomal (Na+ _I- K+)-ATPase from brain cortex. 
The enzyme preparation was incubated with the indicated amounts of the drugs in the medium, as 
described in the text, containing 3 mM K +. The incubations were carried out and the enzyme activity 
was calculated as described in the text. Each experiment, using the same enzyme preparation, was run 
in quadruplicate and the values presented are the averages of three experiments. The standard devia- 
tion about these averages did not exceed 5 per cent of the mean value. 
Striking differences in the inhibition of both enzymes were obtained with the 
benzomorphans,16 (Fig. 3). Whereas all four analogues inhibited the brain enzyme, 
none of them affected the (Na+ + K+)-ATPase from kidney at concentrations shown 
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FIG. 3. Effect of benzomorphans on the microsomal (Na+ i- K+)-ATPase from brain cortex. The 
enzyme preparation was incubated with the indicated amounts of the drugs in the medium, as described 
in the text, containing 3 mM K +. The incubations were carried out and the enzyme activity was 
calculated as described in the text. Each experiment, using the same enzyme preparation, was run in 
quadruplicate and the values presented are the averages of three experiments. The standard deviation 
about these averages did not exceed 5 per cent of the mean value. 
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FIG. 4. Effect of chlorpromazine on the microsomal (Na+ j- K+)-ATPase from cortices of brain and 
kidney. The enzyme preparations were incubated with the indicated amounts of the drug in the 
medium, as described in the text, containing 3 mM K +, The incubations were carried out and the 
enzyme activity was calculated as described in the text. Each experiment, using the same enzyme 
preparation, was run in quadruplicate and the values presented are the averages of three experiments. 
The standard deviation about these averages did not exceed 5 per cent of the mean value. 
in Fig. 3. The most potent inhibitor of the (Na+ + K+)-ATPase from brain was 
etazocine; 0.5 x 10R3 M of the drug caused more than 40 per cent inhibition. 
In agreement with previous reports, 17,18 chlorpromazine was a potent inhibitor of 
the brain (Na* + K”)-ATPase. In addition, it also strongly inhibited the enzyme 
from kidney (Fig. 4). The inhibition of both enzymes was linear with increasing 
concentrations of the drug in the investigated range of Oat-4 x low4 M. 
DISCUSSION 
The reported plasma levels of the drugs producing pharmacologic activity in 
man1g~20 are much lower than those shown to inhibit the (Na+ + K+)-ATPase in the 
present study. However, tissue levels of these basic amines can be expected to be 
considerably higher than their concentrations in p1asma.21*22 The concentrations of 
the central nervous system drugs which significantly inhibited the brain (Na+ + K’)- 
ATPase in vitro8~Z3 ranged from IO-’ to 10e4 M. The tension of diethylether and of 
halothane which produced inhibition of the microsomal (Na+ + K+)-ATPase from 
brain was ten times that of clinical concentrationsS9 
There is no direct evidence for the involvement of the brain (Na’ + K+)-ATPase 
in the mechanism of action of analgesics. When assayed in the absence of ions, the 
activity of the microsomal (Na’ _t K+)-ATPase from brain decreased after chronic 
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morphine treatment of rats, suggesting an interaction between these ions and the drug 
at the active site of the enzyme. 24 A similar relation between the presence of Na+ and 
K+ and the inhibition of this enzyme was reported with imipramine. l l The correlation 
between the effects of these drugs on the (Na + $ K+)-ATPase from the brain and 
their pharmacologic activity has been discussed on the basis of a drug-induced change 
in membrane permeability. 10,25 Since both the general depressants8 and the anti- 
depressant drugs reported here inhibit the brain (Na+ + K+)-ATPase, a common 
phase in the mechanism of action of these two groups of drugs may exist. In view of 
the difference in psychological effects of tricyclic antidepressants and of MAO 
inhibitors,26,27 the distinctly different interaction of these two groups of compounds 
with the (Na+ + K+)-ATPase from brain becomes of particular interest. 
The differential sensitivity of the kidney enzyme to the tricyclic antidepressants and 
benzomorphans is of particular interest and its elucidation deserves further work. 
Concerning the relatively strong inhibition of the kidney enzyme by the tricyclic 
antidepressants, there is an increasing number of reports describing various side 
effects of these drugs. 28-30 It is possible that the effects observed in the present study 
on the (Na+ + K+)-ATPase from kidney are a reflection of the multi-organ pharma- 
cologic actions of these drugs. 
Chlorpromazine, which is known to be a potent inhibitor of the (Na+ -I- K+)- 
ATPase from brain,17*18 was used in this study as a reference compound in order to 
compare the viability of the two enzyme preparations. As can be seen in Fig. 4, the 
drug strongly inhibited the (Na+ + K+)-ATPase from kidney in addition to its 
described effects on the brain enzyme. Interestingly, a linear relation between inhibi- 
tion and concentration of chlorpromazine was obtained with both enzymes. This is in 
contrast to the sigmoidal dose-response curve obtained by the interaction of chlorprom- 
azine free radical with the microsomal (Na+ + K+)-ATPase previously treated with 
deoxycholate and NaI.18 
The interaction of the drugs with the enzyme preparations was studied under three 
different experimental conditions. In incubation series A, both the (Na+ + K+)- 
ATPase and the ouabain-insensitive ATPase were exposed to drug action. In series B, 
prior to the addition of the drugs, the (Na+ + K+)-ATPase was totally inhibited by 
ouabain. This order of addition was reversed in series C, i.e. the enzyme preparation 
was first exposed to the drug, followed by the addition of ouabain. Inhibition of the 
(Na+ + K+)-ATPase by each drug was obtained by subtracting enzyme activity in 
series B or C from that obtained in series A. Except with chlorpromazine, the enzyme 
activities obtained in series C were higher than those in series B in all other instances 
of observed drug inhibition of the (Na+ + K+)-ATPase, suggesting partial blocking 
of the cardiac glycoside site of the enzyme by the drugs. With the brain enzyme, the 
observed differences averaged to 16 f 3 per cent for both the tricyclic antidepressants 
and the benzomorphans. Interestingly, the activity of the (Na+ + K+)-ATPase from 
kidney revealed no difference when assayed in series B and C in the presence of the 
tricyclic antidepressants. 
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